CT-0729 / CARISMA Therap - LARVOL DELTA

CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting (PRNewswire) - “CARISMA Therapeutics…announced study findings accepted for virtual presentation at The American Association for Cancer Research (AACR) Annual Meeting on Saturday, April 10 – Thursday, April 15…A phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors. Anti-HER2 CAR monocytes demonstrate targeted anti-tumor activity and enable a single day cell manufacturing process…Chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models.”

P1 data • Preclinical • Oncology • Solid Tumor